<DOC>
	<DOC>NCT02238132</DOC>
	<brief_summary>To obtain further information on the tolerability of Atrovent速 inhalets in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice</brief_summary>
	<brief_title>Postmarketing Surveillance Study of Atrovent速 Inhalets in Chronic Obstructive Airways Disease</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Ipratropium</mesh_term>
	<criteria>Primarily, Patients with chronic obstructive airways disease Only patients who had not been treated with Atrovent速 in the last year were to be considered for inclusion Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent速 inhalets</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>